Slide 1: Onvansertib Ph 1b/2 mCRC Trial Data Update
Onvansertib Ph 1b/2 mCRC Trial Data Update
Slide 2: Forward-looking statements
Forward-looking statements CERTAIN STATEMENTS IN THIS PRESENTATION ARE FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," “believe,” "forecast," "estimated" and "intend" or other sim
Slide 3: Mark Erlander, Ph.D. Chief Executive Officer
Mark Erlander, Ph.D. Chief Executive Officer
Slide 4: Objective response rate for mCRC trial exceeds SoC over time
Objective response rate for mCRC trial exceeds SoC over time Historical SoC* ORR 11.4% 13% a i ii mg 2008 2013 2017 Onvansertib+SoC ORR (CR+PR) — all doses —— 36% TT 38% Sof 14 12 of 32 1 a io Jan Apr Jul Oct 35% 17 of 487 } Jan 2022 ORR are interim data as of Dec 3, 2021 from an ongoing trial and u
Slide 5: Median progression free survival for mCRC trial exceeds SoC over time
Median progression free survival for mCRC trial exceeds SoC over time Onvansertib+SoC mPFS - all doses Historical SoC* mPFS (months) == 9.4 months 9.4 monthst By 5.6 I ; l 2008 2013 2017 Apr Jul Oa = + Jan 2022 PFS are interim data as of Dec 3, 2021 from an ongoing trial and unlocked database * 2008
Slide 6: Onvansertib positions Cardiff Oncology to effectively target PLK1
Onvansertib positions Cardiff Oncology to effectively target PLK1 SPECIFICITY Exquisitely specific for PLK1 ENZYME PLK1 PLK2 PLK3 CK2 EET CDK1/CycB 42 other kinases and >140 in the Millipore panel 2009; Mito Leukemia an IC5o (uM) 0.002 >10 >10 0.4 0.4 >10 >10 PROPERTIES * Small molecule * Oral dosin
Slide 7: Gaps in current mCRC therapies leave a significant unmet need
Gaps in current mCRC therapies leave a significant unmet need 1st LINE PCS AL NS FOLFOX (chemo) + bevacizumab KRAS Normal + EGFR inhibitor FOLFIRI (chemo) + bevacizumab KRAS Mutant | FOLFOX (chemo) + bevacizumab KRAS Normal! 57.1% et al. Br J Cancer. 2017 Mar 28;116(7):923-929
Slide 8: 2nd line historical ORR 5% 11.4% 13%
2nd LINE HISTORICAL ORR 5% 11.4% 13%
Slide 9: Gaps in KRAS-mutated mCRC therapies leave a significant unmet need
Gaps in KRAS-mutated mCRC therapies leave a significant unmet need KRAS Mutations in mCRC" A G12C Investigational therapies G12D (Amgen; Mirati) address the G12C KRAS mutation only G12V KRAS Normal G13D G12S G12A Q61H G13C 1, Jones R et al. Br J Cancer. 2017 Mar 28;116(7):923-929
Slide 10: Gaps in KRAS-mutated mCRC therapies leave a significant unmet need
Gaps in KRAS-mutated mCRC therapies leave a significant unmet need KRAS Mutations in mCRC" 91.1% of patients with KRAS mutations miss out on G12V targeted therapy
Slide 11: Onvansertib downstream cell cycle mechanism
Onvansertib DOWNSTREAM S G2 G1 M
Slide 12: Katherine Ruffner, MD Chief Medical Officer
Katherine Ruffner, MD Chief Medical Officer
Slide 13: Ph 1b/2 trial of onvansertib in combination with FOLFIRI-bevacizumab
Ph 1b/2 trial of onvansertib in combination with FOLFIRI-bevacizumab in patients with KRAS-mutated mCRC °7|2nd-Line SoC: FOLFIRI + bevacizumab OVOV\O)(@O)@O@)| ¢ || 7 | 8 || 9 || 10) 11 || 12 || 13 || 14 ONVANSERTIB °*|2nd-Line SoC: FOLFIRI + bevacizumab O)(P)(E) (OE) (O)}| 20 || 21 || 22 || 23 || 2
Slide 14: Trial endpoints: disease response and exploratory biomarkers
Trial endpoints: disease response and exploratory biomarkers EFFICACY ENDPOINTS /—~ Primary: Objective Response Rate (ORR) { l ) per RECIST v1.1 in patients who receive ~~ _>1 cycle of treatment Secondary: Progression-Free Survival (2 y: Prog &) (PFS) and Duration of Response (DoR) >. Exploratory: d
Slide 15: Weeks 1-2, weeks 3-4 historical ORR and mPFS
WEEKS 1−2 WEEKS 3−4 HISTORICAL ORR* 5% 11.4% 13% HISTORICAL mPFS* 4.5−5.7 mo 20% ≥6 mo
Slide 16: Enrollment and patient demographics
Enrollment and patient demographics Enrollment* Number of Patients (N) Treated Currently on treatment Total Patients N=50 Age (years) Sex Male Female ECOG! 0 1 Primary tumor site? Colon Rectum Other Phase 1b, Dose LevelO Phase 1b, Dose Level +1 Onvansertib 12 mg/m? Onvansertib 15 mg/m? 6 6 0 1 as of
Slide 17: No major/unexpected toxicities
No major/unexpected toxicities GRADE TEAEs* 1 2 3 4 All • • • GRADE TEAEs* 1 2 3 4 All
Slide 18: Evaluable Patients
Evaluable Patients Jan 2021 As of Sept 16 As of Dec 3 As of Jan 18 Sept 2021
Slide 19: Evaluable Patients data release timeline
Jan 2021 As of Sept 16 As of Dec 3 As of Jan 18 Sept 2021 Evaluable Patients • Webcast data release • –
Slide 20: Clinical benefits observed
Jan 2021 As of Sept 16 As of Dec 3 As of Jan 18 Sept 2021 Evaluable Patients 1 2 3 Clinical benefits observed
Slide 21: Efficacy: 92% disease control rate (DCR)
Efficacy: 92% disease control rate (DCR) Best Radiographic Response® — all doses (as of Dec 3, 2021) 100 0 hs mm Complete Response mm Partial Response mm Stable Disease © Confirmed CR mmm Progressive Disease © Confirmed PR Patients treated at the RP2D e WH 30% tumor reduction % change in target lesi
Slide 22: Efficacy: 92% disease control rate (DCR)
Efficacy: 92% disease control rate (DCR) PR confirmation status Best Radiographic 1. Waiting for confirmatory scan; remains on trial RP2D | 2. Regressed to SD (-31 to -25%); potentially curative surgery All other | 3. Regressed to SD (-32 to -24%); remains on trial doses 4. Discontinued for unrelate
Slide 23: % change in target lesions from baseline
% c h a n g e in t a rg e t le si o ns f ro m b a se lin e
Slide 24: % change in target lesions from baseline
% c h a n g e in t a rg e t le si o n s fr o m b a se lin e % c h a n g e in t a rg e t le si o n s fr o m b a se lin e Patients achieving CR+PR Patients achieving SD
Slide 25: Initial disease responses may occur from week to week
Initial disease responses may occur from week 8 to week 32 —— ——— ° —— s = Swimmer plot? -— all doses (as of Dec 3, 2021) 8s S 8 88 a 8 ° ° 8 0° o oS 8 se °o fe “eo geo oe —_—_— Evaluable Patients — all doses 48 ° e ; Bae 5 eo .2 Time of initial PR % os on treament 8-week scan 8 Cn ar ° S. — so = ca
Slide 26: KRAS Variant CR+PR SD PD Total
KRAS Variant CR+PR SD PD Total 6
Slide 27: ORR continues to exceed the SoC and PoC threshold over time
ORR continues to exceed the SoC and PoC threshold over time Onvansertib+SoC ORR over time (as of Dec 3, 2021) RP2D 2% peg 8 F197 ALL DOSES == 36% ALL DOSES Some 35% 17 of 487 Historical SoC* ORR 5of 14 i 34% RP2D 12 of 357 11.4% 13% 1 ro ' 2008 «8913 ‘Az Jan Apr Jul Oct Jan t Jan 2022 ORR are interi
Slide 28: Median PFS continues to exceed the SoC and PoC threshold over time
Median PFS continues to exceed the SoC and PoC threshold over time Progression free survival! — all doses (as of Dec 3, 2021) Probability of survival Strata 1.00: Months 0 0.75) ; 2008 oso----4 Median PFS ---- ; - 2013 0.255 (9.4 ) _ 2017 1 0.00- v . 6 5 10 15 20 Onvansertib All} 0 9 17 17 18 6 5 10
Slide 29: Predictive response biomarker: change in KRAS MAF
Predictive response biomarker • • CR+PR SD PD -100 -50 0 %Change in KRAS MAF Mean CR+PR -96 SD -74 PD -63 ✱ ✱✱
Slide 30: KRAS-mutated mCRC: Cardiff Oncology's next steps
KRAS-mutated mCRC: Cardiff Oncology’s next steps Cardiff Oncology management has decided to expand the activated Phase 2 trial and enroll ~40-50 additional patients as we prepare for initiation of the pivotal trial * Obtain additional patient data: — Safety — Efficacy — Pharmacokinetic/pharmacodynam
Slide 31: Clinical programs: other combinations
CLINICAL PROGRAMS OTHER COMBINATIONS • • •
Slide 32: Preclinical IND Ph 0/1 Ph status partners
Preclinical IND En. Ph 0/1 Ph 2 Status Partners
Slide 33: DNA damaging agents, microtubule targeting, epigenetics
DNA DAMAGING AGENTS MICROTUBULE TARGETING EPIGENETICS
Slide 34: Our leadership is highly skilled in drug development
Our leadership is highly skilled in drug development Sy, Mark Erlander, PhD Kathrine Ruffner, MD Charles Monahan, RPh Vicki Kelemen CEO CMO SVP, Regulatory coo Tod Smeal, PhD Jamie Levine Brigitte Lindsay CSO CFO VP, Finance
Slide 35: Cardiff Oncology at a glance
Cardiff Oncology at a glance Clinical-stage biotech company developing onvansertib, an oral, highly- selective Polo-Like Kinase 1 (PLK1) inhibitor, to treat cancers with the greatest medical needs for new treatment options Exchange Cash, Cash Equivalents and Investments! Cash used in Operating Activ
Slide 36: Learn more at www.CardiffOncology.com
Learn more at www.CardiffOncology.com
Slide 37: Appendix: Summary of onvansertib mCRC Ph1b/2 trial data over time
Appendix: Summary of onvansertib mCRC Ph1b/2 trial data over time ASCO GI ASCO Gl KOL Event Jan 2022 Investor Webcast Jan 2021 Sept 2021 | Jan 2022 Abstract Poster Dec 3, 2021 + Data Cutoff Date | Nov 1, 2020* July 2, 2021* Sep 16, 2021 Dec 3, 2021 efficacy follow up through Jan. 18 All Doses bee RP